3,655 Shares in CVS Health Co. (NYSE:CVS) Acquired by Nwam LLC

Nwam LLC bought a new stake in shares of CVS Health Co. (NYSE:CVS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,655 shares of the pharmacy operator’s stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Assetmark Inc. grew its stake in CVS Health by 9.7% in the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock valued at $25,781,000 after purchasing an additional 36,132 shares during the last quarter. Cullinan Associates Inc. raised its stake in shares of CVS Health by 43.8% during the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock worth $7,125,000 after acquiring an additional 37,395 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in CVS Health in the second quarter valued at approximately $57,584,000. Oppenheimer Asset Management Inc. grew its holdings in CVS Health by 5.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 448,323 shares of the pharmacy operator’s stock worth $28,191,000 after purchasing an additional 24,285 shares during the last quarter. Finally, CX Institutional lifted its holdings in shares of CVS Health by 698.0% during the 3rd quarter. CX Institutional now owns 74,609 shares of the pharmacy operator’s stock valued at $4,691,000 after purchasing an additional 65,259 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Up 3.6 %

CVS stock opened at $60.10 on Tuesday. The firm’s fifty day moving average is $59.25 and its 200 day moving average is $58.67. The firm has a market cap of $75.63 billion, a PE ratio of 15.25, a P/E/G ratio of 0.98 and a beta of 0.55. CVS Health Co. has a one year low of $52.71 and a one year high of $83.25. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The firm had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $2.21 EPS. On average, research analysts forecast that CVS Health Co. will post 5.43 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were paid a $0.665 dividend. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a yield of 4.43%. CVS Health’s dividend payout ratio is currently 67.51%.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent analyst reports. Evercore ISI upped their target price on CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Barclays decreased their price objective on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. UBS Group boosted their target price on shares of CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Piper Sandler lowered their price objective on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research note on Monday. Finally, StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.33.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.